Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Taran paid only paid net $1,265,831 for all the assets cash, liquid receivables with it's $2 million dollar bid as the assets had a asset value of 736,470. HGEN reported the sale as 'revenue' when it is not really revenue. but capital loss. it's asset were sold like 99% loss. HGEN can claim 100 million in capital loss . Investors valued the assets at over 100 million when ipo so technically a loss if FDA didn't approve their patent. But for some reason the CFO won't report the over 100 million as capital loss. As shell company with over 100 million capital loss it can be sold just tax purpose but management seems to have another agenda. The assets of hgen was valued at over 100 million when it ipo in nasdaq. now the assets are worth 0 that is capital loss of 100 million.
The feb 29 2024 bank summary closing balance as $1,914,245 but if you deduct the $1,265,831 deposits which are the 1 million DIP loan and 265,831 unidentified deposits probably refunds. it only has $914,000 in cash as of feb 29 2024. It paid out or wired out or embezzled out over $991,504 while in chapter 11 bankruptcy. over $350,000 is to some unknown creditor in the US or fake account. which it didn't have to pay because it is in chapter 11.
The humanigen as of feb 29 2024 has NEGATIVE equity value or -42,000 and could be more.
Technically the shares of hgenq is worhtless and reason the 90% shareholder won't sell their 100 million shares is they use the control to embezzle every penny from the bank account of humanigen. The company has no revenue so not sure where it got 736.000 in revenue for the feb 29 ,2024 these fantasy balance sheets and documents or what? Still owes creditors $385,000 even on bogus creditors.
Humanigen feb 29 bank summary shows $350,000 wired out using FED wire and clears same day for a creditor called University of Zurich which is bank in Switzerland that normally uses SWIFT wire if foreign. So that is contradiction FED is for domestic banks while Swift is international. why would the University of Zurich would be in SWIFT it's in Europe. FED is only for domestic bank to bank accounts
another is the $74,444 to humanigenics 5328 ludwig 240227ach which bill payment to who? no explanation, For bankrupt company with no revenues it spent over 1 million in 2 months
I'd like to think that macro-level medical considerations do not have a hand in what transpires here. But as I look forward to a pathway of consensus regarding mRNA vaccines, I also anticipate that a new division will develop in regards to the WHO's role in dictating how our healthcare system functions in the United States. So things may get worse before they get better, if they are able to get better. I'm not optimistic. I don't trust our own federal government to represent our interest, and I suspect a WHO-directed role in the US and world-wide will have an unfortunate amount of support from the British and American public. Objectivity could become further constrained, especially on a small biotech message board.
Let's hope for the best, Brother! For the medical community to awaken to the value of lenz as a traditional vaccine-enhancement, as well as a therapeutic, will be a good thing!
AstraZeneca vaccine victims win court decision for damages, brought on violation of the Consumer Protection Act, and negating AZ's impunity. Will other vaccine manufacturers likewise face damages?
the crime syndicate that runs the OTC markets also fun the CBOE which robbed millions off traders during the 2020 oil crash. fools who thought they got sure win buying oil at $15/oil lost everything when price of futures oil went to -10 and had accounted liquidated. it was impossible to lose money buy oil at $10 that was an opportunity of a lifetime or 30 years. nobody can buy oil at $10/barrel to but for people who bought a $10/barrel the exchange or the exchange mafia syndicate rob their accounts. with negative oil price meaning you had to pay the exchange to own futures contracts and owe them money because the price oil was NEGATIVE value. that is the kind of crooks you are dealing with. You have a winning lottery numbers, they change the numbers. same with price of options, it's b.s. for long term options. the put value is 10% of the share price, it's b.s. in all the financial instruments.
another company also put a dead General in their board of directors to make it look legit.. a former fake US general in his 90's is a board member of a company?
For a company in chapter 11 and only has 4 employees, it manages to borrow money to pay employees the 4 employees $80,706 in one month to ripoff the shareholders. Fire the employees. Ron who is former judge got paid $10,000 for nothing of value, why he still in the payroll.? A former judge in board of directors?
this is classic state assisted theft. okay like US and EU counties stealing private assets for Russian citizens.
Like all the russia oligarchs they bought all the bankrupt state assets for free in the 1990's..from former state owned companies.as the assets were sold in rigged auction. basically the state was robbed of state own asset by private owners or new bougeaous capitalism
Why mafia crime global financial syndicate you work for? The OTC is just front for organize crime and Citadel is front for big boss who owns this 'market' and exchange. they own the SEC too and judges. and the politicians, you clueless peon retail investors don't have clue you are dealing with!
That a boy Goody! Show 'em what for! ....and Jay and Preciouslife1, I'm right there in the cockpit with you. I "ignore" often and this one is quite deserved. Sadists have no place on these boards. Notice she has no followers so, I believe, others agree. Others also have no respect for this person's posts.
Why would I pay to have it removed? I will just hold onto it as it's not the first revoked security I ever held before. I had one from the greys make me a 15,000% gain back in 2019 so anything is possible.
Hello Brother Jay!!! WHEN I SAW "44 OF THAT PERSONS POSTS" STILL HERE; AND MINE WERE DELETED I "ASSUMED" THAT THE MODS FACILITATED THAT AS I USED TO MODERATE LIKE 6 BOARDS AND THEY WOULD NOTOFY ME ABOUT DELETIONS AND WARNINGS TOO ... I APOLOGIZE TO YOU AND ALL HGEN SHAREHOLDERS FOR MY ATTEMPTING TO DEFEND THE BOARD AND COMPANY AGAINST HIS COWARDLY ATTACKS .. SHALOM PEACE TOO ALL ...
corporate embezzlement is modern robbery and in many countries, people get the death sentence for corporate embezzlement if the victime as gov't or ripping off state money.
Watching this chapter alive in the fake court trial is like watch a live robbery happening with police watching and laughing at you fools.
and if managment keeps wiring money and borrowing money the share can have negative value and get delisted. from the OTC markets and you cannot sell it and have to pay your broker $300 to have the ticker removed from your brokerage account.
Why would anyome pay you .40 cents for yoru shares when it's worth only .0001/share
all the assets are sold and only value is some cash and is less than 1 million and dwindling You assume that under chapter 11, the company can delaying making any payments. in one month the company wired out 991,000 to creditors which didn't have to. why pay the lawyer fees anything. for what. The company has less than 1.6 million left and if this continues and henry madrid keeps wiring money out there is no money in the shell company other than shell company with an empty 'promise' that taran may pay you fools any money if the ip patent is approved by FDA. that was bought for nothing. I don't understand why taran wold even loan 1 million to file for chapter. loans like that is for real business with real business operations. the company only has 4 employees and can fire everyone and not pay any creditors and walk and don't appear in court. the person who is in contempt of court is henry madrid. for wiring out money to himself to some swiss bank for $350,000 and another in $60,000 it owes to some lawyer for what.? pushing and filing some papers. As for as chapter 11, this is a disaster for hgenq as an 'entity' it's loss all its asssets which was worth over 2 billion and sold for nothing and still owes moeny. and still management embezzling corporate cash. and these guys lieke dtgoody and cowtown jay ,,they are delusional and too detached to this hgenq ticker like it's emotional attachment to something and still believes it has value. like an expired lottery ticket. your hgen lottery ticket expired worthless.face reality. you've been skewed. but they won't accept reality..
Actually, I have begun 'ignoring' this guy (or these guys) when I see them arrive with a brand new nickname, and an agenda. I see the material on stocktwits, and I gain nothing by seeing it again here. Historically, I never had any poster on ignore, despite so many people advising me to ignore this poster, or that one, over the years. But, Ihub offers the 'ignore' function, and for these virgin antagonists, I use the option to ignore them. There are other, more important issues to focus on.
I don’t think he is doing anything wrong aside from annoying the board with the constant messaging. His posts are relevant, they do have factual data, and this person seems to have a lot of info they dug up…or had handed to them.
They are following the bankruptcy proceeding closer then anyone else I’ve seen posting on the board, they are even posting bank statements on another board.
The question still for me though is why?
There isn’t anything against the iHub tos as far as I can see.
Actually, Chaplain, I haven't deleted any of the posts, lately, many of which were mine. DTG hasn't, either.
If there is a problem, then there is also a reason for the problem.
And any such problem is beyond my authority to fix. I've tried, to the extent that I can. The present situation is unfortunate, and I hope we can return to the fairly good order we had.
Well I have 4.1 million shares of this worthless company. If folks want to waste all of their time bashing the stock then go right ahead and bash away. It has no bearing on me. I have 1 million shares up for sale at .40 cents and the rest will be in the dollars.
why moderating for. cost money to moderate open discussion. moderation is censorship and cost money. the site is free for a reason.
the company currently has less than 30 shareholders okay. and is same as private company
and no trading and no discussion except 10 guys. many sites are not free due to high cost of moderation and censorships etc. why moderate. the site is no liable to what people post on boards. speak your mind or post something useful information. this stock problem is lack of interest from investors and no interest from traders. the trading is indicative of no volume and all the volume is articificial intelligence trading these 100 shares at .0001..why they make these 'fake volume' is another question.
SERIOUSLY MODERATORS, YOU HAVE ALLOWED THIS ONCE GOOD BOARD TO BECOME AN ABSOLUTE JOKE WITH THIS "AN411" CLOWN TO POST AND SPEW ENDLESSLY AND WHEN I "GET TO" SHOW THE INCREDULOUS PAID BASHER NEGATIVITY OF THE CLOWN, MY POSTS GET DELETED ... I AM A SHAREHOLDER, THIS CLOWN WANTS YOU ALL TO SUFFER, TO WALLOW IN YOUR LOSSES ON PAPER TIL NOW . . . . . NOT A GREAT JOB MODS, REALLY YOU CEDED THE BOARD TO A SWAMP DWELLING NON SHAREHOLDER NARCISSIST!!!!! _____ 42 POSTS ON A NEWLY CREATED MARCH 21st BASHER AGENDA
The company currently has no assets. so people keep talking about LENZI being approved by FDA is non-sense
The post-bankruptcy amount balance the company still owed is $385,051 as of feb 29 2024
The post-bankruptcy amount balance the company still owed was $229,800 as of jan 31 ,2024
how the balance still ow $155,251 more in debt after chapter 11===legal fees.
What is the point of paying all these legal fees for?
If it was person declaring bankruptcy, they just walk and tell the FAKE creditor 'claims' to get lost. The company has no revenues why even have ron barlian the board of directors and henry madrid as CFO..there is only 4 employees. left.
considering it pre-bankruptcy of 44 million which 31 million was 'disputed' $385,000 is cost of bills for legal fees. the company actually paid the $350,000 university of zurich in some swiss bank account which it didn't have to. and the $27,000 still on the former 27 million ''lawsuit' . Why patheon any money for cancelling a contract. they want $27,000 cancellation fee in bankrutpc court. humanigen most valuable asset is technically sold for nothing due to the frivolous lawsuit.
Humanigen before 2022 july 13 had and enterprise value over 100 million value and when it ipo on nasdaq it book shows assets over 100 million the min. asset value to be listed in Nasdaq and had millions in cash. Humanigen didn't have debts in incurred prior to July 13 2022 it was FDA’s rejection of Humanigen drug highlights problems in developing Covid-19 treatments. and as result of the 27 million and 4.3 million in lawsuit and 3 million shareholder lawsuit as result of the rejection of the FDA of the drug Lensizlaud . FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19.
Because of the 30 million liability or lawsuit, the company cannot raise new additional investor cash. companies like humanigen are funded by investors that keeping funding for research and submission of clinical trial data which cost millions.
The company doesn't even own the Lenz patent and auctioned for zero value. An asset once worth 2 billion IF approved by FDA. in 2021 Now the question is why would anyone pay 2 million for some ip or asset supposedly worth ZERO.
Why would Taran buy the contracts. All contracts of hgen are discharged. isn't it in chapter 11.
Not a single biotech even bother to bid for the assets. Either it's worthless and too messy and lead to expensive legal litigation with any buyer of the 'ip' due to many conditions on the sale of the ip. or assets. The buyer of the assets had obligation to the seller which detered any potential buyer. Essentially in business terms, any bidder was bidding for an asset that had a lien or liability. on the auction for the humanigen assets. that is why nobody would even register to bid. it was an auction but closed or restricted auction or bogus auction or rigged auction.
Yes, I am saying that we can resubmit the EUA, and obtain a favorable decision, with the data, as written. Adding additional data from the ACTIV-5 patients in ordinal scale 5, and adding the PREACH-M trial results, would just be window dressing, and allow some face-saving for the FDA.
Our LIVE-AIR trial data was sufficient in volume, and exemplary in result. The trial results stand on their own. That fact is irrefutable, and I stand by that conclusion.
Thousands of people are still suffering preventable deaths from covid every week. So to me, there is nothing comical about the facts.
Doctors, independently, know how corrupt the FDA is, and they don't speak out. But I think they will, when the WHO starts dictating how they are to run their practices, and treat their patients. I don't know how woke the AMA is, but I hope they will be forced by their membership to defend their medical sovereignty.
The document you posted does not lead to that conclusion . How did you interpret that data as saying that they still owe $385k? The DIP loan gets converted to a consideration against the APA . So the $2 million was available to settle debts . All post petition debts would also get discharged , if they are not new liabilities and are merely resubmission of claims, Question was, what is the amount of cash on hand, that the company will have after discharging all debts? Is that 0? That is the only asset they will have .
It goes back to the question that Jay had? Why was the filing not converted into chapter 7 ? That’s something I am curious about . What’s the revival plan ? Does the company have employees left ? If it does not what happens next ?
Hgen management thé , FDA , the trustee and the market did not come to that conclusion . When everybody and the market was expecting an EUA from the live air results , the FDA rejected the EUA application . The market price of HGEN crashed 90%. Later when everybody and the market felt the NIH active five trials will yield the data for an EUA, the trial failed to meet the end point and the company and we didn’t even apply for any Eua as management felt the data cannot be used to make an application . The market crashed again another 90%. The company went through bankruptcy because it couldn’t service the debts , because of the expensive Covid trials , and that caused the prices to crash another 99%. And now you are telling everybody we can use that data to generate an EUA? That’s rather comical isn’t it . It’s like applying salt to the wound of the shareholders .
A shell company has no revenue so how will it repay any debt. and no assets.
The question they paid 500,000 or almost 1 million in legal fees and all the shareholder got was bankruptcy all assets sold an still owe $385,000.? What was the point of chapter 11. other than to close the books in these stock scheme. and somebody made millions on it and got off clean.
if this company still had the LENZ and owns the patents it they can raise additional shareholder money and raise 10 million but not with 44 million in liabilities. whether they are disputed or not.lawsuits are considere debt or liabilities no investors would touch a company with lawsuits.
The company has no money or cash and still owes $385,000? who will pay the $385,000..And the dip loan. why would Durrant give the company a 1 million dollar loan for. the risk is repaymen of the 1 million loan if management embezzles or has to repay creditors. why give the loan for. As for Lenz, hgenq doesn't own any assets. it's shell company and all creditors claims should have been discharged. wasted enough time of the two judges and 3 months peoples time in a bogus fake bankruptcy filing. Only loser were the 180 million they raised in 2021 and shareholders. who lost buying the shares when it was trading above $3. and think it would get FDA approval.
The company still owes $27,000 of the pathogen's bogus $27 million lawsuit claim which was. the company should countersue pathogen for $5 million for making fake creditor claims okay! and same with the Chime 7.3 million initially it was 4.3 million but increased to 2 million because it feels like it creditor claim and $3 million fake lawsuit. It was these 44 million fake creditor lawsuits why the company had to file bankruptcy as no investors would invest in a company that is in legal ligitation or that was the plan to bankrupt the company and makes shares worthless. skewing the investors who bought at average cost of $3.
Feb 29 2024 humanigen creditor released. The company now after all assets sold and 44 million creditor claim reduced to 385,000
Chime and pathogen, over 44 million creditor claim discharged. The question why did humanigen wire $350,000 to some university of Zurich bank account for? The account could be fake account in swiss bank which has no identification needed to open a swiss bank account.or fake documents use to open a swiss bank account. There is only 3 employees and one board that is paid $10,000 for his time. So the company spent half a million dollars in legal fees and still owes $385,000? all the creditor claims except a salaries and legal fees should be paid. What relationship or business does the university of zurich does humanigen with that entity, there is no vendor invoice or work completed documents.
The data from the LIVE-AIR patient population would be of sufficient volume for the FDA to make a regulatory decision. Trial size was established in consultation between the FDA and management.
The NIH ACTIV-5 trial tested late stage patients, including patients who had, or were on, IMV. The FDA even included patients on ECMO, whose outcomes were not to be factored into the trial results.
No new trial is required for an EUA. We should be able to extract ACTIV-5 results for their patients who were in ordinal scale 5, and use those results as an adjunct to the LIVE-AIR trial results, if necessary. The ACTIV-5 patients in ordinal scales 6 and 7 were too progressed in disease severity, and were not included in LIVE-AIR. We also have safety and efficacy data from lenz on the PREACH-M study, which may soon win approval in Australia, and all of this data could be included in a resubmission of our EUA application. I think our OS is already higher than management wants, and I doubt they will reverse split, even at 1:5. There will be no need to do so, anyway, after the loaned shares are recalled, and we could even see a forward split, which I hope we don't, even f it would be temporary.
That’s not entirely true . What happens to the cash which is lying there given as part of APA.
Agreed , the live AIR trial met the end point . However at that time, the data was deemed not sufficient to get a EUA. That’s why the data from the NIH trial was needed to get to that end point . However as many noted the primary end point was not met . Now we can all agree or disagree , but any new path way for an EUA or a BLA would require a new trial with hundreds of millions of dollars. Something the company cannot raise . As a shareholder I would not support any such irresponsible decisions . Also we no longer own lenz . This point is moot unless a reverse merger happens . And I don’t see a pathway for it yet . Even if there is one , existing shareholders would find their holdings diluted to a large extent . Maybe a 5:1 or a 10:1 . With that kind of dilution , they will find themselves completely sidelined .
Welcome to the room, SorcererGuru44, and thank you for your considerate post.
Folks keep your post on Topic! No Personal, Religious, or Political Post Please!!!
Good news for Invivyd (IVVD), and signals Regulatory stance on mAbs.
"March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc...today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19."
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-interim-exploratory-data-vyd222-ongoing-canopy
Invivyd is defining 'pre-exposure' differently than I am accustomed to seeing. They are not saying their mAb is for covid-naive patients. They're saying just the opposite.
"Exploratory data such as provided in today’s update are important for broad reflection as they represent some of the first data from a clinical trial conducted with a monoclonal antibody in a population that has acquired prior immune exposure from either vaccination or natural infection. By contrast, studies of prior authorized COVID-19 PrEP mAbs largely relied on participants required by protocol to be naïve to vaccination or prior infection." I guess the mass vaccination assault expanded the allowable definition of 'pre-exposure prophylaxis.'
In addition to the above Release Details, Invivyd also issued Release Details, which mentions the EUA.
https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-fda-authorization-emergency-use-pemgardatm
I'm actually encouraged by this.
"A PREP Act declaration is specifically for the purpose of providing immunity from liability"
https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx
It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43270
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |